MediWound Ltd. (NASDAQ:MDWD - Get Free Report)'s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $15.48 and traded as low as $13.03. MediWound shares last traded at $13.29, with a volume of 86,155 shares.
Analyst Ratings Changes
Several analysts have issued reports on MDWD shares. Oppenheimer reaffirmed an "outperform" rating and set a $30.00 target price (down from $32.00) on shares of MediWound in a research report on Friday, August 14th. Wall Street Zen lowered MediWound from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MediWound in a research report on Friday, July 17th. Finally, HC Wainwright reiterated a "buy" rating and issued a $36.00 target price on shares of MediWound in a report on Thursday, May 28th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $33.00.
View Our Latest Analysis on MDWD
MediWound Stock Up 0.6%
The firm has a market cap of $170.78 million, a PE ratio of -7.38 and a beta of 0.14. The stock has a 50 day moving average price of $14.00 and a two-hundred day moving average price of $15.48.
MediWound (NASDAQ:MDWD - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). The company had revenue of $3.09 million during the quarter, compared to analysts' expectations of $2.59 million. MediWound had a negative net margin of 170.10% and a negative return on equity of 47.24%. As a group, equities analysts anticipate that MediWound Ltd. will post -2.31 earnings per share for the current year.
Insider Transactions at MediWound
In other MediWound news, COO Shmuel Hess sold 3,958 shares of the firm's stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $12.92, for a total value of $51,137.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 9.20% of the company's stock.
Hedge Funds Weigh In On MediWound
Hedge funds have recently made changes to their positions in the company. Quarry LP purchased a new position in MediWound in the 4th quarter worth $26,000. BNP Paribas Financial Markets grew its stake in MediWound by 90.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 723 shares during the last quarter. California State Teachers Retirement System grew its stake in MediWound by 281.4% during the 2nd quarter. California State Teachers Retirement System now owns 2,014 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,486 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in shares of MediWound by 69.1% in the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 649 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company's stock valued at $85,000 after purchasing an additional 999 shares during the period. 46.83% of the stock is owned by institutional investors and hedge funds.
MediWound Company Profile
(
Get Free Report)
MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.
The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
